{"id":21104,"date":"2025-01-01T19:01:23","date_gmt":"2025-01-01T18:01:23","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/01\/01\/a-method-for-screening-functional-anti-treg-antibodies-using-a-treg-like-cell-linekirsten-pfeffer-on-31-de-december-de-2024-at-1100\/"},"modified":"2025-01-01T19:01:23","modified_gmt":"2025-01-01T18:01:23","slug":"a-method-for-screening-functional-anti-treg-antibodies-using-a-treg-like-cell-linekirsten-pfeffer-on-31-de-december-de-2024-at-1100","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/01\/01\/a-method-for-screening-functional-anti-treg-antibodies-using-a-treg-like-cell-linekirsten-pfeffer-on-31-de-december-de-2024-at-1100\/","title":{"rendered":"A method for screening functional anti-Treg antibodies using a Treg-like cell line\u200bKirsten Pfeffer   on 31 de December de 2024 at 11:00"},"content":{"rendered":"<div>\n<p><b>J Leukoc Biol<\/b>. 2024 Dec 31:qiae257. doi: 10.1093\/jleuko\/qiae257. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Regulatory T cells can suppress activated T cell proliferation by direct cell-contact, although the exact mechanism is poorly understood. Identification of a Treg-specific cell surface molecule that mediates suppression would offer a unique target for cancer immunotherapy to inhibit Treg immunosuppressive function or deplete Tregs in the tumor microenvironment. In this study, we explored a method of whole cell immunization using a Treg-like cell line (MoT cells) to generate and screen monoclonal antibodies that bound cell surface proteins in their native conformations and functionally reversed Treg-mediated suppression. From the 105 hybridomas that bound to the MoT cell surface, a functional screen utilizing conventional Treg suppression assays revealed 32 candidate antibodies that exhibited functional activity (reversed or enhanced suppressive activity). As an example, we characterized one anti-MoT mAb, 12E7, that exhibited strong binding to MoT cells and conventional Treg cell surfaces. This candidate antibody was subsequently found to bind to a potential suppressive target, CD44, and demonstrated the ability to partially reverse MoT and conventional human Treg-mediated suppression.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39739859\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=8405628&amp;ff=20250101130122&amp;v=2.18.0.post9+e462414\">39739859<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jleuko\/qiae257\">10.1093\/jleuko\/qiae257<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Leukoc Biol. 2024 Dec 31:qiae257. doi: 10.1093\/jleuko\/qiae257. Online ahead of print. ABSTRACT Regulatory T cells can suppress activated T cell proliferation by direct cell-contact, although the exact mechanism is poorly understood. Identification of a Treg-specific cell surface molecule that mediates suppression would offer a unique target for cancer immunotherapy to inhibit Treg immunosuppressive function &#8230; <a title=\"A method for screening functional anti-Treg antibodies using a Treg-like cell line\u200bKirsten Pfeffer   on 31 de December de 2024 at 11:00\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/01\/01\/a-method-for-screening-functional-anti-treg-antibodies-using-a-treg-like-cell-linekirsten-pfeffer-on-31-de-december-de-2024-at-1100\/\" aria-label=\"Read more about A method for screening functional anti-Treg antibodies using a Treg-like cell line\u200bKirsten Pfeffer   on 31 de December de 2024 at 11:00\">Read more<\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86,42],"tags":[],"class_list":["post-21104","post","type-post","status-publish","format-standard","hentry","category-journal-of-leukocyte-biology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/21104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=21104"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/21104\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=21104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=21104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=21104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}